Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Icon is well-positioned for growth in the contract research industry thanks to its focus on oncology and metabolic diseases, as well as its use of advanced technologies to improve trial management. However, potential risks such as regulatory changes and delays in clinical trials could impact the company's performance. Investors should closely monitor these potential risks while considering Icon's strong bookings and potential for future buybacks in 2026.

Bears say

Icon is currently facing several challenges, including passthrough volatility, cancellation concerns, and margin compression due to a higher proportion of passthrough services. These challenges have led to uncertainty surrounding reported book-to-bill figures and make it difficult to accurately forecast future financial performance. Additionally, the company may face headwinds if biopharma industries reduce outsourcing to clinical CROs or if there is increased competition for talent, leading to wage inflation and lower margins. These factors, along with potential headwinds from stagnant or reduced R&D spending by biopharma companies, contribute to a negative outlook on Icon's stock.

ICON (ICLR) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 12 analysts, ICON (ICLR) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.